33469-11-3

Usage

Uses

Used in Pharmaceutical Development:
Benzonitrile, 4-[5-(trifluoroMethyl)-1H-iMidazol-2-yl]is used as a building block in the synthesis of various pharmaceutical compounds for its potential biological activity and ability to interact with biological systems.
Used in Research:
Benzonitrile, 4-[5-(trifluoroMethyl)-1H-iMidazol-2-yl]is used as a research compound to explore its potential applications in the development of new drugs and understanding its interactions with biological systems.
Used in Material Science:
Benzonitrile, 4-[5-(trifluoroMethyl)-1H-iMidazol-2-yl]may have potential applications in material science, although specific uses are not detailed in the provided materials.
Used in Organic Chemistry:
Benzonitrile, 4-[5-(trifluoroMethyl)-1H-iMidazol-2-yl]may also have uses in the field of organic chemistry, but the exact applications are not specified in the provided materials.

Upstream product

• 105-07-7 4-cyanobenzaldehyde 
• 431-67-4 1,1-dibromo-3,3,3-trifluoroacetone 

Relevant academic research and scientific papers

SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS

The present disclosure provides compounds having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein X1, X2, X11, X12, R1, R3, R5, R5', R6, and R7 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to inhibit a USP1 protein and/or to treat a disorder responsive to the inhibition of USP1 proteins and USP1 activity. Compounds of the present disclosure are especially useful for treating cancer.

PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS

The application relates to inhibitors of USP1 useful in the treatment of cancers, and other USP1 associated diseases and disorders, having the Formula: (I), where R1, R2, R3, R3', R4, R5, X1, X2, X3, X4, and n are described herein.

Trifluoromethylimidazoles and a method for their preparation

4(5)-Trifluoromethylimidazoles having optional substituents in the 1 and 2 positions are provided. The novel 4(5)-trifluoromethylimidazoles are prepared by reacting a 1,1-dihalo-3,3,3-trifluoroacetone compound with an appropriate carboxaldehyde and ammoni

2-Pyrazinyl-trifluoromethylimidazoles and a method for their preparation

4(5)-Trifluoromethylimidazoles having optional substituents in the 1 and 2 positions are provided. The novel 4(5)-trifluoromethylimidazoles are prepared by reacting a 1,1-dihalo-3,3,3-trifluoroacetone compound with an appropriate carboxaldehyde and ammoni

4-Trifluoromethylimidazoles and 5-(4-pyridyl)-1,2,4-triazoles, new classes of xanthine oxidase inhibitors.

The syntheses of a number of 2-substituted 4-trifluoromethylimidazoles and 3-substituted 5-(4-pyridyl)-1,2,4-triazoles are described. The trifluoromethylimidazoles were prepared from 3,3-dibromo-1,1,1-trifluoroacetone after hydrolysis with aqueous sodium acetate solution and condensation with an aldehyde in the presence of ammonia. Basic hydrolysis of the trifluoromethyl group was found to provide a facile method for the synthesis of imidazole-4-carboxylic acids. In the imidazole series a 2-aryl substituent and a free imino group were required for xanthine oxidase inhibitory activity. The triazoles were obtained through the reaction of an aroylhydrazine and an imino ether followed by thermal ring closure of the intermediate acylamidrazone. As in the imidazole series, a free imino group is an absolute requirement for in vitro activity. Additional structure-activity relationships of these compounds are presented.